CPC-114 PREVALENCE AND MANAGEMENT OF DRUG-RELATED PROBLEMS IN AN INTENSIVE CARE UNIT

doi:10.1136/ejhpharm-2013-000276.571

1K Lundereng, 1UK Sund, 2HM Sporson, 4R Pedersen, 5E Molden. 'Levanger Hospital Pharmacy Trust, Central Norway Hospital Pharmacy Trust, Levanger, Norway; 2Central Norway Hospital Pharmacy Trust, Central Norway Hospital Pharmacy Trust, Trondheim, Norway; 3Oslo Hospital Pharmacy Trust, South-eastern Norway Hospital Pharmacy Trust, Oslo, Norway; 4Department of Emergency Medicine and Intensive Care Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway; 5School of Pharmacy, University of Oslo, Oslo, Norway

Background Patients admitted to intensive care units (ICUs) are at higher risk than other patients of having problems, injuries and adverse drug reactions (ADRs) associated with their drug treatment.

Purpose To identify and categorise drug-related problems (DRPs) in an intensive care unit, using a standardised tool modified for use in critically ill patients.

Materials and Methods The Integrated Medicines Management model (IMM) was used as a standardised tool for both medicines reconciliation and medication reviews. All patients admitted to the Intensive Care Unit (ICU) at Levanger Hospital, Norway, during a 12-week period in 2011 were asked to participate in the study. DRPs identified by the pharmacist were discussed with the physicians in charge and changes in drug treatment were recorded.

Results A total of 23 patients were included in the study and 94 medication reviews were conducted (1–25 reviews per patient). One or more DRPs were identified for 16 of the patients. Overall 150 DRPs were identified by the pharmacist. Out of these 41% were related to discrepancies with the medicines list, 18% were non-optimal doses, 8% clinically relevant interactions and 8% non-optimal treatment. Input from the pharmacist was upheld by the physician and the medicine changed as suggested for 15% of the DRPs related to the medicines reconciliation and discrepancies with the medicines list and for 76% for DRPs identified in the medication review.

Conclusions DRPs were frequently identified in this cohort of ICU patients by the use of a standardised assessment tool. The majority of DRPs identified in the medication reviews were accepted by the physician. This indicates that the inclusion of a clinical pharmacist in the ICU multidisciplinary team may contribute to the quality of both acute and prophylactic drug treatment in critically ill patients.

No conflict of interest.

CPC-115 PREVENTION AND TREATMENT OF INTRALUMINAL CATHETER THROMBOSIS IN CHILDREN HOSPITALISED IN A PAEDIATRIC INTENSIVE CARE UNIT

doi:10.1136/ejhpharm-2013-000276.572

1A de Lorenzo-Pinto, 1AC Sánchez-Galindo, 1S Manrique-Rodríguez, 1OM Fernández-Llamazares, 1SN Fernández-Lafever, 1M García-San Prudencio, 1B Marzial-Alfaro, 1L Cortesjó-Fernández, 1M Sanjurjo-Sáez. 1Hospital General Universitario Gregorio Marañón, Pharmacy Department, Madrid, Spain; 2Hospital General Universitario Gregorio Marañón, Pediatric Intensive Care Unit, Madrid, Spain

Background Placing central venous access devices (CVADs) is essential in the management of critically ill children. Used for the administration of fluids, medicines, total parenteral nutrition or blood products they may, however, also cause thrombotic complications.

Purpose To develop and implement a protocol for the prevention and treatment of catheter-related intraluminal thrombosis in a Paediatric Intensive Care Unit (PICU).

Materials and Methods A computerised search was carried out on MEDLINE using the medical subject heading ‘central venous catheter’ associated with ‘occlusion’, ‘thrombosis’, ‘critically ill patients’ and ‘fibrinolytic’. The protocol development process was guided by the goal of weighing evidence regarding effectiveness, safety and cost. Algorithms were developed in order to reduce the complexity of the protocol, aid comprehension, and facilitate successful implementation.

Results With the information gathered, a protocol was drawn up and those recommendations that best suit our environment were included. They were agreed upon by a broad panel of professionals working in the PICU and the Pharmacy Department. Facts to highlight:

- Prevention of intraluminal catheter thrombosis:
  - Prevention of intraluminal CVAD thrombosis with continuous heparin infusion: To keep intravenous catheters patent for drug administration, haemodynamic monitoring and blood sampling.
  - Prevention of intraluminal CVAD thrombosis with heparin lock solutions: To maintain catheters not being used for the administration of continuous infusion fluids.
  - Prevention of intraluminal CVAD thrombosis with fibrinolytic lock solutions: If prior intraluminal thrombosis has occurred. The fibrinolytic agent used should be the same as that used for thrombosis resolution.

- Treatment of intraluminal CVAD thrombosis
  - Normal saline: Flush with 5–10 mL. If after 3 attempts the problem is not solved, administration of fibrinolytic therapy is recommended.
  - Urokinase at a concentration of 5,000 U/mL (first line).
  - Alteplase at a concentration of 1 mg/mL (second line).

Conclusions Due to the variety of options available for the pharmacotherapeutic management of intraluminal catheter thrombosis, one measure to improve the quality of the treatment and reduce the variability in prescriptions could be to implement a protocol as described.

No conflict of interest.
Clinical pharmacy and clinical trials

Conclusions

The campaign was a success, but more could be done to improve the outcomes of such a campaign. It is important to consider the selection of wards to include in the campaign. On wards where the patients are discharged after a few days it can be difficult to implement the interventions under time pressure.

No conflict of interest.

CPC-117 PROSPECTIVE REGISTRY FOR EVALUATING THE EFFECTIVENESS OF BEVACIZUMAB ALONE OR WITH IRINOTECAN IN RECURRENT GLOBLASTOMA

doi:10.1136/ejhpharm-2013-000276.574

M Vianio,1 M Cecchi,1 S Colombari,2 E Agostino,2 F Attanasio,1 M Ceroti,1 R Banfi.1
1Careggi Hospital, Pharmacy Department, Florence, Italy; 2ISPQ, Molecular and Nutritional Epidemiology Unit, Florence, Italy

Background

Recurrent glioblastoma is nearly always fatal, with median survival rates of approximately 12–14 months. Previous phase II clinical trials showed promising results with bevacizumab, alone or in combination with irinotecan, in patients with recurrent glioblastoma.

Purpose

To assess whether the survival of patients with recurrent glioblastoma receiving bevacizumab alone or with irinotecan in everyday practice is comparable to that reported in clinical trials.

Materials and Methods

This was a retrospective observational study conducted at a single hospital in Italy. Patients with recurrent glioblastoma who had received bevacizumab alone or with irinotecan from January 2009 to September 2011 were included in our study.

The main outcome measures were progression-free survival (PFS), overall survival (OS), and rates of PFS and OS at 6 months.

Results

Median PFS was 5.1 months in the bevacizumab group (n = 9) and 15.4 months in the bevacizumab + irinotecan group (n = 10), with 6-month PFS rates of 45% and 69%, respectively.

Median OS was 6.8 months for bevacizumab alone and 11.1 months for bevacizumab + irinotecan, with 6-month OS rates of 100% and 90%, respectively.

Conclusions

Although the number of patients included is not sufficient to allow a conclusive statement about the place of bevacizumab in the treatment of recurrent glioblastoma, the data appear promising, and are consistent with the results of clinical trials.

No conflict of interest.

CPC-119 RANDOMIZED CONTROLLED TRIAL OF CLINICAL PHARMACY MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES IN AN OUTPATIENT DIABETES CLINIC IN JORDAN

doi:10.1136/ejhpharm-2013-000276.575

A Jarab,1 S Alqudah,1 T Mukattash,1 G Shattat,1 T Al-Qirim.1
1 Alzaytoonah University of Jordan, Pharmacy, Amman, Jordan; 2Jordanian Royal Medical Services, Pharmacy, Amman, Jordan; 3Jordan University of Science and Technology, Pharmacy, Irbid, Jordan

Background

Glycaemic goals are often not achieved in patients with type 2 diabetes despite the availability of many effective treatments and the documented benefits of glycaemic control in the reduction of long-term microvascular and macrovascular complications.

Purpose

To evaluate, in a randomised, controlled trial, the impact of a clinical pharmacy service on clinical outcomes in patients with type 2 diabetes.

Materials and Methods

A total of 171 patients (85 intervention vs. 86 usual care) participated in the study. Intervention patients had individualised education and treatment recommendations from a clinical pharmacist while control patients received usual care provided by the clinic. The primary outcome measure was glycaemic control manifested by HbA1c reductions. All other data collected including systolic and diastolic blood pressure, total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), serum triglycerides, medication adherence, and necessary self-care activities formed secondary outcome measures. Between-group differences in the amounts of change from baseline to 6-month follow-up were tested and a p value of <0.05 was considered statistically significant.

Results

Compared with baseline values, patients in the intervention group had a mean reduction of 0.8% in HbA1c versus a mean